Radiology Department IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
Aliment Pharmacol Ther. 2020 Nov;52(10):1563-1573. doi: 10.1111/apt.16069. Epub 2020 Sep 4.
Identifying predictors of therapeutic response is the cornerstone of personalised medicine.
To identify predictors of long-term healing of severe inflammatory lesions based on magnetic resonance enterography (MRE) findings in patients with Crohn's disease (CD) treated with tumour necrosis factor alpha (TNF-α) inhibitors.
This prospective longitudinal single-centre study included patients with clinically active CD requiring treatment with TNF-α inhibitors with at least one intestinal segment with a severe inflammatory lesion detected by MRE (segmental MaRIA ≥11). MRE data were obtained at baseline, and at weeks 14 and 46. The primary endpoint was healing of severe inflammatory lesions (MaRIA <11) in each segment. The secondary endpoint was healing of all severe inflammatory lesions on a per-patient analysis.
We included 58 patients with 86 intestinal segments with severe inflammatory lesions. At week 46, healing of severe lesions was found in 51/86 (59.3%) segments, and complete healing of inflammatory lesions in all segments was found in 28/58 (48.6%) patients. Multivariable analysis found baseline-negative predictors of long-term healing of severe inflammation were ileal (as opposed to colonic) location (OR 0.00, [0.00-0.56] P = 0.002) and presence of creeping fat on MRE (OR 0.00 [0.00-0.57]; P = 0.001). Persistence of segmental MaRIA score >10.6 at week 14 was a negative predictor of healing at week 46 (OR 0.3 [0.04--0.38]; P < 0.001).
In patients with CD, the absence of creeping fat detected at baseline MRE and location of severe inflammatory lesions are clinically relevant predictors of long-term healing of severe inflammation under treatment with TNF-α inhibitors.
确定治疗反应的预测因素是个体化医学的基石。
根据接受肿瘤坏死因子-α(TNF-α)抑制剂治疗的克罗恩病(CD)患者的磁共振肠造影(MRE)结果,确定严重炎症病变长期愈合的预测因素。
本前瞻性纵向单中心研究纳入了需要接受 TNF-α抑制剂治疗且 MRE 检测到至少一个肠段存在严重炎症病变(节段性 MaRIA≥11)的临床活动期 CD 患者。在基线时以及第 14 周和第 46 周获得 MRE 数据。主要终点是每个节段严重炎症病变的愈合(MaRIA<11)。次要终点是每位患者所有严重炎症病变的愈合。
我们纳入了 58 例 86 个肠段存在严重炎症病变的患者。在第 46 周时,86 个节段中有 51 个(59.3%)节段的严重病变得到愈合,28 例(48.6%)患者所有炎症病变完全愈合。多变量分析发现,长期严重炎症愈合的基线阴性预测因素是回肠(而非结肠)部位(OR 0.00,[0.00-0.56] P=0.002)和 MRE 上存在爬行脂肪(OR 0.00 [0.00-0.57];P=0.001)。第 14 周时节段性 MaRIA 评分>10.6 持续存在是第 46 周愈合的阴性预测因素(OR 0.3 [0.04-0.38];P<0.001)。
在 CD 患者中,基线 MRE 检测到无爬行脂肪和严重炎症病变的位置是 TNF-α 抑制剂治疗下严重炎症长期愈合的临床相关预测因素。